Everything below concerns GLP-1 analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-13. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
According to his notes, Cushing visited her next about a week later on February 13, at which point the bill was paid and he declared that she was in a "normal condition." The next day she sent a letter to Julius Dresser, a fellow student of Quimby and future critic of Eddy, telling him that she had fallen on the sidewalk, was "taken up for dead, came to consciousness... but to find [herself] the helpless cripple [she] was before [she] saw Dr. Quimby." She further stated that despite the physician's predictions, she had gotten out of bed and walked by herself; but now she was frightened and wanted Dresser's help. On March 2, Dresser sent a letter declining her request, suggesting she could do more for herself than he could, and refusing to step into Quimby's shoes as a healer. Eddy's letter was later used by Milmine to accuse Eddy of basically making up the whole thing, saying that in asking Dresser for help, it showed she had not fully recovered. Huge Studdert Kennedy writes that her asking for help may have been occasioned by her fear of previous experiences with relapses from physical difficulties, particularly under Quimby's treatment. Milmine's critical McClure's biography also claimed that she wasn't really injured much or at all to begin with; in 1908 they solicited an affidavit from Cushing in which he stated he never took Eddy's injury to be serious, and never heard anything about a miraculous cure. He also stated that it was he, and not God, that cured her.
=== Severity (staging) and progression (grading) === The most recent (2017) periodontal disease classification uses CAL as a major factor in assessing both Severity and Progression. Alongside other factors like radiographic bone loss and tooth loss. CAL correlates to severity (Staging) as follows.
=== Differential diagnosis === Due to the comparative rarity of NMS, it is often overlooked. Immediate treatment for the syndrome should not be delayed as it has a high mortality of between 10-20%. Differentiating NMS from other neurological disorders can be very difficult. The diagnosis is suggested on patients with a history of drug exposure to the most common inducing agents such as strong antidopaminergic medications. The differential diagnosis includes serotonin syndrome, encephalitis, toxic encephalopathy, status epilepticus, heat stroke, catatonia and malignant hyperthermia. Substance intoxication from stimulant drugs, such as cocaine, amphetamine, or methamphetamine may also produce similar symptoms. Features which distinguish NMS from serotonin syndrome include bradykinesia, muscle rigidity, and a high white blood cell count.
==== Bones ==== Together with [18F]sodium floride, PET for bone imaging has been in use for 60 years for measuring regional bone metabolism and blood flow using static and dynamic scans. Researchers have recently started using [18F]sodium fluoride to study bone metastasis as well.
Sources: en.wikipedia.org
This results in the outflow of monoamines from synaptic vesicles into the cytosol (intracellular fluid) of the presynaptic neuron, and their subsequent release into the synaptic cleft by the phosphorylated transporters. Other transporters that methamphetamine is known to inhibit are SLC22A3 and SLC22A5. SLC22A3 is an extraneuronal monoamine transporter that is present in astrocytes, and SLC22A5 is a high-affinity carnitine transporter. Methamphetamine is also an agonist of the alpha-2 adrenergic receptors and sigma receptors with a greater affinity for σ1 than σ2, and inhibits monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). Sigma receptor activation by methamphetamine may facilitate its central nervous system stimulant effects and promote neurotoxicity within the brain. Dextromethamphetamine is a stronger psychostimulant, but levomethamphetamine has stronger peripheral effects, a longer half-life, and longer perceived effects among heavy substance users. At high doses, both enantiomers of methamphetamine can induce similar stereotypy and methamphetamine psychosis, but levomethamphetamine has shorter psychodynamic effects.
In aerospace structural health monitoring, in situ inspection involves diagnostic techniques that assess components within their operational environments, avoiding the need for disassembly or service interruptions. The nondestructive testing (NDT) methods commonly used for in situ damage detection include infrared thermography, which measures thermal emissions to identify structural anomalies but is less effective on low-emissivity materials; speckle shearing interferometry (shearography), which analyzes surface deformation patterns but requires carefully controlled environmental conditions; and ultrasonic testing, which uses sound waves to detect internal defects in composite materials but can be time-intensive for large structures. Despite these individual limitations, the integration of these complementary techniques yields higher overall diagnostic accuracy. Another approach involves real-time monitoring using alternating current (AC) and direct current (DC) sensor arrays. These systems detect structural degradation, including matrix discontinuities, interlaminar delaminations, and fiber fractures, by analyzing variations in electrical resistance and capacitance within composite laminate structures.
Desalting and buffer exchange are methods to separate soluble macromolecules from smaller molecules (desalting) or replace the buffer system used for another one suitable for a downstream application (buffer exchange). These methods are based on gel filtration chromatography, also called molecular sieve chromatography, which is a form of size-exclusion chromatography. Desalting and buffer exchange are two of the most common gel filtration chromatography applications, and they can be performed using the same resin. Desalting and buffer exchange both entail recovering the components of a sample in whatever buffer is used to pre-equilibrate the small, porous polymer beads (resin). Desalting occurs when buffer salts and other small molecules are removed from a sample in exchange for water (with the resin being pre-equilibrated in water). Buffer exchange occurs when the buffer salts in a sample are exchanged for those in another buffer.
== Uses in sintering == The sintering process is taking a powder, putting it into a mold and heating it to below its melting point. Sintering is based on atomic diffusion, the atoms in the powder particle diffuse into surrounding particles eventually forming a solid or porous material. It has been discovered that Li2TiO3 powders have a high purity and good sintering ability.
== Attempted murder trials == In 1982, von Bülow was arrested and tried for the attempted murders of Sunny on two occasions in two consecutive years. The main medical and scientific evidence against him was that Sunny had low blood sugar, common in many conditions, but a blood test showed a high insulin level. The test was not repeated. A needle was used as evidence against von Bülow in court, with the prosecution alleging that he had used it and a vial of insulin to try to kill his wife. His mistress of two years, the soap opera actress Alexandra Isles, testified "He said that they had been having a long argument, talk, about divorce that had gone on late into the night. She had drunk a great deal of eggnog. And then he said, 'I saw her take the Seconal.' And then he said that the next day when she was unconscious that he watched her knowing that she was in a bad way, all day, and watched her and watched her. And finally, when she was at the point of dying, he said that he couldn't go through with it and he called (the doctor) and saved her life." The discovery of these items became the focal point of von Bülow's appeal. At the trial in Newport, Rhode Island, von Bülow was found guilty and sentenced to 30 years in prison; he appealed, hiring Harvard Law School professor Alan Dershowitz to represent him. Dershowitz served as a consultant to the defence team led by Thomas Puccio, a former federal prosecutor.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.